Ovid Therapeutics was founded in 2014 with the mission to develop transformative medicines for people with rare and orphan diseases of the brain. Our research focuses on conditions with overlapping symptoms and/or molecular pathways (a series of interactions that results in changes in a cell). With this approach, we are building a company with deep knowledge of and expertise in the way the brain functions. Each milestone we achieve is expected to bring significant scientific insights to our team and to unexplored neurological disorders. Over time we believe we will create an unparalleled knowledge of how the brain functions in key pathological areas, starting with neurodevelopment and epilepsy.
Our pipeline today is built around disorders with few or no treatment options. Angelman syndrome is one of these conditions. We’re committed to understanding the challenges faced by patients and their families, and are working to develop medicines that transform their lives.
Learn more about Angelman syndrome, meet the inspirations behind our work and find resources to help navigate a diagnosis.